Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Celgene reports more apremilast data

Celgene Corp. (NASDAQ:CELG) reported additional data for apremilast on Monday and also announced revenue guidance for the oral phosphodiesterase-4

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE